Pharmaceutical manufacturer contractor Kalderos has replaced Review, its 340B drug claims verification tool, with a new one named Discount Hub.
Avita, a leading provider of 340B contract pharmacy and third-party administration services geared toward HIV and LGBTQ+ communities, is expanding into medical practice staffing and management.
Please Login or Become a Paid Subscriber to
Walgreens Boots Alliance (WBA) announced September 20th that it is acquiring the remaining 30% stake in 340B specialty pharmacy company Shields Health Solutions that it did not already own.
Please Login or Become a Paid Subscriber to
Community health center advocates have strongly criticized a new Kaiser Health News (KHN) investigative report that found that some health centers have large profit margins.
Please Login or Become a Paid Subscriber to View
The brand drug industry’s recent full-page ad in The Washington Post saying the 340B program helps big hospitals and chain pharmacies but not patients is “hypocritical slander,” AIDS Healthcare Foundation President Michael Weinstein said last week.
A Special Report From 340B Report:
A two-part series on the growing frustrations safety net providers face in restoring access to 340B pricing in the contract pharmacy setting. Part 1 provides important background on the challenges that covered entities
Hospital outpatient pharmacy leaders cite staffing shortages, managing multiple vendors, and navigating insurer red tape—specialty drug referrals and prior authorization requirements, specifically—among top workplace challenges, a new survey finds. As 340B providers continue to grapple with pharmaceutical manufacturer
…
340B pharmacy and health-system services provider CPS Solutions, based in Dublin, Ohio, has announced it had acquired specialty pharmacy services company Trellis Rx, headquartered in Atlanta, Ga.
Please Login or Become a Paid Subscriber
Pharmacy care services company OptumRx is requiring 340B covered entities to get its consent before they share OptumRx contract pharmacy claims data with drug manufacturers to satisfy manufacturers’ conditions on 340B pricing.